Literature DB >> 26471486

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.

Tamara Alpermann1, Susanne Schnittger1, Christiane Eder1, Frank Dicker1, Manja Meggendorfer1, Wolfgang Kern1, Christoph Schmid2, Carlo Aul3, Peter Staib4, Clemens-Martin Wendtner5, Norbert Schmitz6, Claudia Haferlach1, Torsten Haferlach7.   

Abstract

Entities:  

Keywords:  AML; DNMT3A mutation; FLT3-ITD; NPM1 mutation; molecular genetics; prognosis

Mesh：

Substances：

Year:  2015        PMID： 26471486      PMCID： PMC4938334          DOI： 10.3324/haematol.2015.133819

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   11.047


× No keyword cloud information.
  9 in total

1.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

2.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Authors:  Brunangelo Falini; Cristina Mecucci; Enrico Tiacci; Myriam Alcalay; Roberto Rosati; Laura Pasqualucci; Roberta La Starza; Daniela Diverio; Emanuela Colombo; Antonella Santucci; Barbara Bigerna; Roberta Pacini; Alessandra Pucciarini; Arcangelo Liso; Marco Vignetti; Paola Fazi; Natalia Meani; Valentina Pettirossi; Giuseppe Saglio; Franco Mandelli; Francesco Lo-Coco; Pier-Giuseppe Pelicci; Massimo F Martelli
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

3.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Authors:  Konstanze Döhner; Richard F Schlenk; Marianne Habdank; Claudia Scholl; Frank G Rücker; Andrea Corbacioglu; Lars Bullinger; Stefan Fröhling; Hartmut Döhner
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

4.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

Authors:  Christian Thiede; Sina Koch; Eva Creutzig; Christine Steudel; Thomas Illmer; Markus Schaich; Gerhard Ehninger
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

5.  Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.

Authors:  Roel G W Verhaak; Chantal S Goudswaard; Wim van Putten; Maarten A Bijl; Mathijs A Sanders; Wendy Hugens; André G Uitterlinden; Claudia A J Erpelinck; Ruud Delwel; Bob Löwenberg; Peter J M Valk
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

6.  Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

Authors:  Susanne Schnittger; Claudia Schoch; Wolfgang Kern; Cristina Mecucci; Claudia Tschulik; Massimo F Martelli; Torsten Haferlach; Wolfgang Hiddemann; Brunangelo Falini
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

7.  Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.

Authors:  Thomas Büchner; Richard F Schlenk; Markus Schaich; Konstanze Döhner; Rainer Krahl; Jürgen Krauter; Gerhard Heil; Utz Krug; Maria Cristina Sauerland; Achim Heinecke; Daniela Späth; Michael Kramer; Sebastian Scholl; Wolfgang E Berdel; Wolfgang Hiddemann; Dieter Hoelzer; Rüdiger Hehlmann; Joerg Hasford; Verena S Hoffmann; Hartmut Döhner; Gerhard Ehninger; Arnold Ganser; Dietger W Niederwieser; Markus Pfirrmann
Journal:  J Clin Oncol       Date:  2012-09-10       Impact factor: 44.544

8.  Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype.

Authors:  Youngil Koh; Juwon Park; Eun-Kyung Bae; Kwang-Sung Ahn; Inho Kim; Soo-Mee Bang; Jae-Hoon Lee; Sung-Soo Yoon; Dong Soon Lee; Young Yiul Lee; Seonyang Park; Byoung Kook Kim
Journal:  Int J Hematol       Date:  2009-05-30       Impact factor: 2.490

9.  The NPM1 mutation type has no impact on survival in cytogenetically normal AML.

Authors:  Friederike Pastore; Philipp A Greif; Stephanie Schneider; Bianka Ksienzyk; Gudrun Mellert; Evelyn Zellmeier; Jan Braess; Cristina M Sauerland; Achim Heinecke; Utz Krug; Wolfgang E Berdel; Thomas Buechner; Bernhard Woermann; Wolfgang Hiddemann; Karsten Spiekermann
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240
  9 in total
  20 in total

1.  A novel type of NPM1 mutation characterized by multiple internal tandem repeats in a case of cytogenetically normal acute myeloid leukemia.

Authors:  Nicolas Duployez; Lydia Chebrek; Nathalie Helevaut; Elise Fournier; Maxime Bemba; Aurélie Caillault; Sandrine Geffroy; Claude Preudhomme
Journal:  Haematologica       Date:  2018-06-14       Impact factor: 9.941

2.  Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.

Authors:  Fei Yang; Tauangtham Anekpuritanang; Richard D Press
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

3.  Discovery of cancer common and specific driver gene sets.

Authors:  Junhua Zhang; Shihua Zhang
Journal:  Nucleic Acids Res       Date:  2017-06-02       Impact factor: 16.971

Review 4.  Mutations in AML: prognostic and therapeutic implications.

Authors:  Courtney D DiNardo; Jorge E Cortes
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

5.  Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML.

Authors:  Alison E Meyer; Cary Stelloh; Kirthi Pulakanti; Robert Burns; Joseph B Fisher; Katelyn E Heimbruch; Sergey Tarima; Quinlan Furumo; John Brennan; Yongwei Zheng; Aaron D Viny; George S Vassiliou; Sridhar Rao
Journal:  Leukemia       Date:  2022-07-01       Impact factor: 12.883

6.  Prevalence and Clinical Significance of FLT3 and NPM1 Mutations in Acute Myeloid Leukaemia Patients of Assam, India.

Authors:  Jina Bhattacharyya; Sukanta Nath; Kandarpa Kumar Saikia; Renu Saxena; Sudha Sazawal; Manash Pratim Barman; Dushyant Kumar
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-28       Impact factor: 0.900

7.  Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates.

Authors:  Xiaorong Gu; Quteba Ebrahem; Reda Z Mahfouz; Metis Hasipek; Francis Enane; Tomas Radivoyevitch; Nicolas Rapin; Bartlomiej Przychodzen; Zhenbo Hu; Ramesh Balusu; Claudiu V Cotta; David Wald; Christian Argueta; Yosef Landesman; Maria Paola Martelli; Brunangelo Falini; Hetty Carraway; Bo T Porse; Jaroslaw Maciejewski; Babal K Jha; Yogen Saunthararajah
Journal:  J Clin Invest       Date:  2018-07-17       Impact factor: 14.808

8.  NPM1 gene mutations can be confidently identified in blood DNA months before de novo AML onset.

Authors:  Pedro M Quiros; Muxin Gu; Clea Barcena; Vivek Iyer; George S Vassiliou
Journal:  Blood Adv       Date:  2022-04-12

9.  Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification.

Authors:  Rina Kansal
Journal:  Cancer Biol Med       Date:  2016-03       Impact factor: 4.248

10.  Correlation of NPM1 Type A Mutation Burden With Clinical Status and Outcomes in Acute Myeloid Leukemia Patients With Mutated NPM1 Type A.

Authors:  Su Yeon Jo; Sang Hyuk Park; In Suk Kim; Jongyoun Yi; Hyung Hoi Kim; Chulhun L Chang; Eun Yup Lee; Young Uk Cho; Seongsoo Jang; Chan Jeoung Park; Hyun Sook Chi
Journal:  Ann Lab Med       Date:  2016-09       Impact factor: 3.464
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.